Sinopharm Hyundai announced that its wholly-owned subsidiary Sinopharm Wichida received a notice from the State Drug Administration that the amoxicillin and clavulanate potassium dry suspension passed the generic drug consistency evaluation. The active ingredient of this drug has antibacterial effects. In 2025, the sales volume of public medical institutions and urban pharmacies nationwide was 279 million yuan. Up to now, the project has invested about 16.23 million yuan in R&D. Previously, the 0.3125g specification passed the evaluation in December 2024. This time, it will promote product market expansion and sales, but there is no significant impact on current results, and there is uncertainty about drug sales.

Sinopharm Hyundai announced that its wholly-owned subsidiary Sinopharm Wichida received a notice from the State Drug Administration that the amoxicillin and clavulanate potassium dry suspension passed the generic drug consistency evaluation. The active ingredient of this drug has antibacterial effects. In 2025, the sales volume of public medical institutions and urban pharmacies nationwide was 279 million yuan. Up to now, the project has invested about 16.23 million yuan in R&D. Previously, the 0.3125g specification passed the evaluation in December 2024. This time, it will promote product market expansion and sales, but there is no significant impact on current results, and there is uncertainty about drug sales.